Navigation Links
Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
Date:11/9/2009

SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. The comments were made by Novartis' CEO, Daniel Vasella, in an interview with The Wall Street Journal. http://www.chinabiotoday.com/articles/20091103_1

HTDS' Chinese subsidiary, Mellow Hope, is the exclusive agent of Zhejiang Tianyuan Bio-pharmaceutical for International marketing and sales. Zhejiang Tianyuan Bio-pharmaceutical has been granted a H1N1 license on September 24, 2009 by the Chinese government agency, SFDA.

Terry Yuan, HTDS' President/CEO said "We believe that when you start to appreciate what Novartis' commitment to our partner in China fully means, and the see the large financial commitment to our partner just for the China market, you can begin to appreciate the enormous value to HTDS of our exclusive international marketing and sales relationship with Zhejiang Tianyuan Bio-Pharmaceutical. Further, the more you appreciate this value, the more you will find yourself understanding our value to them when they appointed us exclusive agent for international marketing and sales. As Mellow Hope owns all of registrations, clinical trials and brands for Zhejiang Tianyuan's international markets, the new Novartis-Zhejiang-Tianyuan entity will continue to leverage our assets and expertise in its international market. The Novartis purchase was announced by Novartis-Zhejiang-Tianyuan on N
'/>"/>

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
2. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
3. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
4. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
5. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
6. Novartis and Sony Pictures Television Internationals Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
7. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
8. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
9. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
10. Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... CA (PRWEB) May 01, 2015 TROY ... the Cerner Southeast Regional User Group (RUG) Conference in ... Cerner Southeast Regional User Group Conference provides a forum ... vendors who support all aspects of electronic medical record ... of Cerner software applications. , In addition to sponsoring ...
(Date:5/1/2015)... 01, 2015 Hope For The Warriors® ... Hope For The Warriors® and military families. All American ... Hope For The Warriors®, a national nonprofit dedicated to ... and restoring hope for our service members and our ... American Ford collected and matched small autograph fee from ...
(Date:5/1/2015)... The fields of genetics and genomics, the ... genes with one another and the environment, is rapidly ... LabRoots, the premier producer of interactive virtual events for ... its annual conference spotlighting the recent advances in Genetics ... Genomics 2015 , a two-day event presented entirely online ...
(Date:5/1/2015)... Washington, D.C. (PRWEB) May 01, 2015 Today ... campaign is expanding its fundraising efforts to help protect the ... the first new program support country added since Girl Up ... Day fundraising campaign aimed at supporting adolescent girls in the ... years Girl Up has supported the advancement of adolescent girls ...
(Date:5/1/2015)... 2015 Digital technology and Wi-Fi-enabled medical ... between prenatal appointments, a preliminary study has ... sample of low-risk pregnant women, will be presented as ... Medical Faculty Associates at the 2015 American Congress of ... May 2-6. The digital technology used was developed by ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 2Health News:United Nations Foundation’s Girl Up Campaign Announces New Funding Initiative to Support Adolescent Girls in India 3Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 2Health News:Mobile Technology May Be Effective in Monitoring Pregnant Women Between Office Visits, Study Shows 3
... The Duke Human Vaccine Institute today announced a ... Diagnostics to enable the rapid development of a ... pandemic virus threat such as pandemic influenza. The ... utilize resources of the National Institute of Allergy ...
... 14 (HealthDay News) -- Parents who say "um" and "uh" ... they,re actually helping the children learn language more efficiently, according ... 30 months found that older children paid more attention to ... the item stumbled and said, "Look at the, uh..." ...
... More intensive or family-based HIV prevention interventions may ... and stop engaging in risky sexual behavior, say researchers ... Juvenile offenders are at increased risk for contracting HIV ... have sex at earlier ages, have more sexual partners, ...
... 2011 An international consortium of scientists, including ... that the "one-size fits all" strategy of uniformly ... for patients with high on-treatment platelet reactivity does ... and stent thrombosis after percutaneous coronary intervention (PCI). ...
... French and Spanish . , A ... Antonio Campos and Miguel Alaminos (histologists), Mara del Mar Prez, ... the ophthalmologist Miguel Gonzlez Andrades, University Hospital San Cecilio, Granada, ... extracted pig corneal cells and replaced them with human stem ...
... , THURSDAY, April 14 (HealthDay News) -- Home safety ... small children, according to a new study. Researchers ... groups of families with newborns. One set of families ... homes, including stairway gates, cabinet locks, electrical outlet covers, ...
Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Better HIV prevention interventions needed for juvenile offenders 2Health News:Better HIV prevention interventions needed for juvenile offenders 3Health News:Antiplatelets: 1 person, 1 dose? 2Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2
(Date:5/1/2015)... 1, 2015  CytRx Corporation (CYTR), a biopharmaceutical ... reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical ... in the early months of 2015, including the ... of aldoxorubicin in patients with soft tissue sarcoma, ...
(Date:5/1/2015)... , May 1, 2015  Boston Scientific Corporation ... its continued business momentum and long-term growth strategies at ... New York City . President and Chief ... unique opportunities the company has to bring forward meaningful ... growing markets and deliver shareholder value. ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 2Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 3Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 4Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 5Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 6Boston Scientific Outlines Growth And Expansion Strategy At 2015 Investor Day 7All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... 05, 2007 /PRNewswire/ -- Results from,the primary ... study showed that 77 percent of treatment-experienced ... tablets with,100 mg ritonavir (PREZISTA/r) twice daily, ... (ARV) agents, reached a,plasma viral load of ...
... Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company specializing ... two Phase III clinical trials for its ... severe,seasonal allergic rhinitis, commonly known as hay ... in both placebo and,PreHistin-treated patient groups, thereby ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5
... The NIDEK YC-1800 is an ... laser delivery and output technologies, improved ... offset and compact design with versatility ... YC-1800 replaces the YC-1600 and adds ...
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
... • V-shaped bottom allows easy ... lips facilitate pour-out ,• Nesting ring ... Solution Basin designed for 4, 8, and ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: